AzTrials
AzTrials

PCOS (Polycystic Ovary Syndrome)Beef+NCT07780188

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

A study testing Beef+ in people with PCOS (Polycystic Ovary Syndrome) and Obese Adolescents, run by Texas A&M University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored dietary intervention which will be termed "Beef+", that will emphasize the incorporation of… Read more about this study

Who is it for?
Ages 11 to 17 years, women only
What is being tested?
Beef+
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteUnited States
Study dates
1 Sep 2026to 30 Apr 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 11 to 17 years
  • Women only
  • No healthy volunteers
  • Child

Who may be able to join

  • Female Adolescent
  • 11-17 years old
  • Suspected or confirmed diagnosis of PCOS
  • ≥1-year post-menarche
  • BMI ≥85th percentile for age/height
  • Able to read and speak English

Who cannot join

  • Medications affecting glucoregulation, metabolic health, and/or appetite (e.g., metformin, GLP-1)
  • Unable or unwilling to eat beef
  • Pregnant or planning pregnancy during study
  • HbA1c ≥6.5%
  • Unwilling or unable to complete study procedures
  • Conditions affecting ability to complete study procedures or the intervention such as gastrointestinal diseases or syndromes, bleeding disorders, ongoing or unresolved eating disorder)
Show all 10Show fewer
  • Conditions affecting reproductive function other than PCOS
  • Conditions that may interfere with continuous glucose monitor (CGM) application or use, including dermatological conditions such as eczema or allergies/reactions to medical adhesives
  • Conditional Exclusion Criteria:
  • Current use of hormonal contraceptives if in the suspected PCOS group (allowable if current for at least the previous 3 months with physician-confirmed PCOS)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Heidi K Vanden Brink, PhD, MSc, RDMS contact

979-321-7073

heidi.vandenbrink@ag.tamu.edu

United States1 site, 1 recruiting
  • Texas A&M AgriLife

    College Station, Texas, 77843

    Heidi Vanden Brink, 979--321-7073, heidi.vandenbrink@ag.tamu.edu

    Michele Garant, DO

    Recruiting

Other trials in United States

About this study

Official title: Effect of Increasing Lean Beef Intake as Part of a Healthy Meal Plan on Glycemic Control in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored dietary intervention which will be termed "Beef+", that will emphasize the incorporation of unprocessed, lean beef (<10% fat) as part of a healthy meal plan to improve glycemic control, diet quality, and health-related quality of life

Read the detailed description

Youth-onset Type 2 Diabetes (T2D) is a chronic disease characterized by accelerated beta cell decline and severe insulin resistance (IR). Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a well-established independent risk factor for youth-onset T2D. A first line of treatment for PCOS is lifestyle intervention; however, there is a paucity of evidence evaluating the effectiveness of nutritional strategies in adolescents with PCOS. The overarching goal of the pilot study, termed Beef+, is to replace intake of high fat, processed red meat products with lean beef ("Beef") prepared as part of healthy meals that target increased vegetable and complex carbohydrate intake per the Dietary Guidelines for Americans ("+") and reducing intake of saturated fat, sodium, and added sugar. We will test the hypothesis that incorporating lean beef as part of a healthy meal plan will improve glucoregulation (Aim 1), enhance overall diet quality and satiety (Aim 2), and be a feasible and acceptable dietary intervention strategy that improves participant and household health-related quality of life (Aim 3).

Being tested
Beef+
Keywords
Dietary Intervention, Polycystic Ovary Syndrome (PCOS), Adolescents, Randomized Control Trial
Medical subject headings
Polycystic Ovary Syndrome, Overweight, Menstruation Disturbances, Hirsutism, Hyperandrogenism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Beef+Other

    Adolescents will be instructed to consume a minimum of 1 (3oz) serving per day of cooked unprocessed, lean (<10% fat) beef (21 oz/week) for 12 weeks. To facilitate adoption, the intervention will be offered at the household level, but it is not a requirement. The intervention is a multi-modal behavior change intervention with three overarching components: modifying beef intake, consuming beef in healthy meals, and the research team purchasing the beef needed for the intervention. To facilitate adoption of lean beef as part of a healthy diet, a study RDN will meet with the participant and at least one representative parent/guardian at bi-weekly check-ins to provide tailored dietary support and develop an implementation plan. A financial supplement of $100/month will be provided offset grocery costs.

Study groups in NCT07780188
Study groupRoleWhat they receive
Control/Usual Lifestyle with optional Delayed InterventionNo interventionParticipants randomized to usual lifestyle will continue with their usual lifestyle/ diet. Participants will undergo all scheduled study procedures. Upon completion of the 12-week of usual lifestyle, participants randomized to the delayed onset control group will be offered one month of the dietary intervention. The delayed intervention is optional.
Beef+ExperimentalNot described
Receives: Other: Beef+

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c

    HbA1c measured as point of care using A1CNow+ point-of-care analyzer, HbA1c will also serve as a safety endpoint.

    Measured: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle

Secondary outcomes (13)
  1. Change in 2-hour Fasting Glucose

    Derived from a 75g oral glucose tolerance test (OGTT) as a measure of glycemic variability

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  2. Dropout rate

    Drop-out and the reason for drop-out will be recorded, and in both the intervention and usual lifestyle groups will be reported.

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  3. Change in Matsuda Index

    Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  4. Change in Insulinogenic Index

    Derived from the 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  5. Change in Disposition Index

    Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  6. Change in 2nd Phase Insulin Release

    Derived from a 75g oral glucose tolerance test (OGTT), as a measure of insulin sensitivity

    Measured: Baseline and Week 12 of Intervention or Usual Lifestyle

  7. Change in Time in Range

    Derived from blinded Continuous Glucose Monitor (CGM) wear, a measure of glycemic variability

    Measured: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle

  8. Change in Continuous Overall Net Glycemic Action (CONGA)

    Derived from blinded Continuous Glucose Monitor (CGM) wear, as a metric of glycemic variability

    Measured: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle

  9. Change in Glycemic Risk Assessment in Diabetes Education (GRADE)

    Derived from blinded Continuous Glucose Monitor (CGM) wear, measure of glycemic variability

    Measured: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle

  10. Change in Diet Quality - Dietary Recalls

    This will be assessed from 24-hour diet recalls and evaluated via Healthy Eating Index (HEI).

    Measured: Baseline and Week 14

  11. Change in Diet Quality - Skin Carotenoids

    Skin carotenoids will be measured through the Veggie Meter ®, which uses reflection spectroscopy to estimate skin carotenoid levels. Three scans will be taken on your non-dominant ring finger. After each scan, a dial gauge and a score will appear on the screen. A final score, calculated as the average of the three scans, will range from 0 to 800. Higher scores indicate greater fruit and vegetable intake.

    Measured: Baseline and Week 14

  12. Change in Perceived Hunger

    This will be measured through an Appetite/Satiety Questionnaire adapted from commonly used appetite assessment methods and previously applied in dietary intervention research. Participants will report their general appetite and satiety experiences using six items assessing hunger frequency, strength of hunger before meals, fullness after eating, desire to eat when food is available, thoughts about food, and satisfaction after eating. Responses are recorded using a 100-mm visual analogue scale implemented as a 0-100 slider (0 = lowest intensity or frequency; 100 = highest intensity or frequency). Participants will be instructed to move the slider to reflect how strongly each statement describes their typical experience. Data collected will be used to evaluate changes in perceived hunger and fullness throughout the intervention.

    Measured: Baseline and Week 14

  13. Change in incident Pre and Type 2 Diabetes

    Type 2 Diabetes is defined as HbA1c >6.5%.

    Measured: Baseline, Week 6, and Week 12 of Intervention or Usual Lifestyle

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion30 Apr 2028 (estimated)
  4. Study completion30 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07780188
Sponsor's protocol ID
IRB#STUDY2026-0483
Other IDs
#2681, Lab Research Funds
Acronym
Beef+
Status last verified
Aug 2026
First submitted
7 Aug 2026
Last updated
21 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data is not anticipated to be shared on a publicly available database because this is not a federally funded study and given the nature of the data collected and vulnerable population.

Questions about this trial

What is this clinical trial studying?

A study testing Beef+ in people with PCOS (Polycystic Ovary Syndrome) and Obese Adolescents, run by Texas A&M University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Heidi K Vanden Brink, PhD, MSc, RDMS (979-321-7073, heidi.vandenbrink@ag.tamu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c (time frame: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in